Get the Stockscreener App
3.88
2.14%
-0.0849
After Hours:
3.56
-0.32
-8.25%
Titan Pharmaceuticals Inc De stock is traded at $3.88, with a volume of 48,258.
It is down -2.14% in the last 24 hours and down -3.72% over the past month.
See More
Previous Close:
$3.9649
Open:
$3.965
24h Volume:
48,258
Relative Volume:
1.94
Market Cap:
$3.55M
Revenue:
$61,000
Net Income/Loss:
$-6.17M
P/E Ratio:
-6.807
EPS:
-0.57
Net Cash Flow:
$-6.43M
1W Performance:
+0.52%
1M Performance:
-3.72%
6M Performance:
-40.40%
1Y Performance:
-42.94%
1-Day Range:
$3.64
$4.2947
1-Week Range:
$3.55
$4.2947
52-Week Range:
$3.51
$14.80
Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile
Name
Titan Pharmaceuticals Inc De
Sector
Industry
Phone
(650) 244-4990
Address
400 OYSTER POINT BLVD, SAN FRANCISCO
Compare TTNP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTNP
Titan Pharmaceuticals Inc De
|
3.88 | 3.55M | 61,000 | -6.17M | -6.43M | -8.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.98 | 119.49B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.26 | 82.89B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
624.96 | 37.37B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.72 | 32.85B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.70 | 27.50B | 3.30B | -501.07M | 1.03B | -2.1146 |
Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-19 | Initiated | Maxim Group | Buy |
| Nov-10-17 | Downgrade | ROTH Capital | Buy → Neutral |
Titan Pharmaceuticals Inc De Stock (TTNP) Latest News
Titan Pharmaceuticals faces Nasdaq compliance issues - Investing.com
Titan Pharmaceuticals Faces Double Nasdaq Compliance Challenge Over Filing, Audit Issues | TTNP Stock News - StockTitan
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan
Conduit Pharma Secures Key Patent for Autoimmune Drug AZD1656 in Major Japan Market | CDT Stock News - StockTitan
Lexicon Pharmaceuticals Appoints Former Eisai CEO Ivan Cheung to Board of Directors | LXRX Stock News - StockTitan
Melt Pharma's MELT-300 Shows Breakthrough Results in Phase 3 Sedation Trial | HROW Stock News - StockTitan
Napo Therapeutics Wins 'Best Pharma Innovator' Award, Advances Rare Disease Drug Trials | JAGX Stock News - StockTitan
Catalyst Pharmaceuticals CEO to Present at Major Healthcare Conferences | CPRX Stock News - StockTitan
Virpax Pharmaceuticals Raises $5M to Advance Pain Management Drug Development | VRPX Stock News - StockTitan
CNS Pharmaceuticals Completes 252-Patient Enrollment in Pivotal Brain Cancer Study | CNSP Stock News - StockTitan
Elite Pharmaceuticals Revenue Surges 33% to $18.9M, Operating Profit Jumps 84% | ELTP Stock News - StockTitan
TFF Pharmaceuticals Announces Complete Shutdown, Appoints Wind-Down Specialist as CEO | TFFP Stock News - StockTitan
Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan
Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug | VRPX Stock News - StockTitan
Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan
Universe Pharmaceuticals Announces 15:1 Reverse Stock Split Amid NASDAQ Concerns | UPC Stock News - StockTitan
Acurx Pharma Q3: New Patent Win & Trial Progress Despite Cash Decline to $5.8M | ACXP Stock News - StockTitan
Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan
Longboard Pharma Launches Groundbreaking Phase 3 Trial for Rare Epilepsy Treatment | LBPH Stock News - StockTitan
CERo's Cancer Drug Shows Breakthrough: Kills Ovarian Cancer Without Toxicity in Key Study | CERO Stock News - StockTitan
Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan
Citius Phase 1 Trial Shows 27% Response Rate with LYMPHIR-Keytruda Combo in Cancer Study | CTXR Stock News - StockTitan
InMed Announces 1-for-20 Reverse Split to Maintain Nasdaq Listing | INM Stock News - StockTitan
NRx Pharmaceuticals Sets Q3 2024 Earnings Call for November 14 | NRXP Stock News - StockTitan
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan
Ionis Pharmaceuticals to Present at 6 Major Healthcare Investor Conferences | IONS Stock News - StockTitan
Amylyx Reports Mixed Q3: Positive Trial Data Despite $72.7M Loss, Cash Runway Into 2026 | AMLX Stock News - StockTitan
Elite Pharmaceuticals (ELTP) to Host Q2 FY2025 Earnings Call on November 15 | ELTP Stock News - StockTitan
Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - StockTitan
InMed Gets Nasdaq Lifeline: 20:1 Share Consolidation Plan to Avoid Delisting | INM Stock News - StockTitan
Bionoid Pharma Unveils 5-Year AI-Powered Growth Strategy, Targets 15% EBITDA | BINP Stock News - StockTitan
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Acadia Pharma Sells FDA Priority Review Voucher for $150M, Boosts R&D Pipeline | ACAD Stock News - StockTitan
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement - StockTitan
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline | CDT Stock News - StockTitan
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - StockTitan
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - StockTitan
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - StockTitan
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer - StockTitan
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - StockTitan
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 - StockTitan
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 - StockTitan
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call - StockTitan
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - StockTitan
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib) - StockTitan
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 - StockTitan
Titan Pharmaceuticals Inc De Stock (TTNP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
3.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):